Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSUMMIT-Jr pediatric juvenile psoriatic arthritis study of ustekinumab or guselkumab
2023-507144-36-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, open-label trial of ustekinumab and guselkumab in juvenile psoriatic arthritis (JPsA) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Ustekinumab steady-state trough concentration and population PK model-predicted AUCss at Week 28, Ustekinumab ACR Pedi 30 at Week 24 and 2 more. Started Apr 2023; status: completed.
02
Drugs
ustekinumabguselkumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2023-507144-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507144-36-00.